Tag Archives: FDA

Drug Costs and Congress: Investments, Contributions and You

A scathing new article on Congress and its financial conflicts of interests with drug and device companies appears in STAT, a news firm specializing in health and science. It examines Senators and Representatives who have oversight of the FDA and … Continue reading

Posted in health insurance, medical bankruptcy, Medicare, pharmaceutical companies, policy and politics, prescription drugs, public dialogue, technology and pharmaceutical costs | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Special Report: Worth the Cost and Benefit? Drugs and Devices–Who Decides?

This is a second of a two part series on health care technology costs, benefits, effectiveness and safety.  At $152 million dollars, a new cancer proton therapy facility sits on the campus of Northwest Hospital in Seattle, Washington, a joint … Continue reading

Posted in business, consumer protection, Health Care Reform, health insurance, health promotioin, Medicare | Tagged , , , , , , , , , , , , , , , , | Leave a comment